Portal de Periódicos da CAPES

All the Postgenomic World is a Stage: The Actors and Narrators Required for Translating Pharmacogenomics into Public Health

2013; Future Medicine; Volume: 10; Issue: 3 Linguagem: Inglês

10.2217/pme.13.10

1744-828X

Edward S. Dove, Vural Özdemir,

Genetics, Bioinformatics, and Biomedical Research

Personalized MedicineVol. 10, No. 3 EditorialFree AccessAll the postgenomic world is a stage: the actors and narrators required for translating pharmacogenomics into public healthEdward S Dove‡ & Vural Özdemir‡Edward S Dove‡Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine, McGill University, 740 Drive Penfield Avenue, Suite 5200, Montreal, QC H3A 0G1, Canada and Columbia Law School – LL.M. Program, New York, NY, USA & Vural Özdemir‡* Author for correspondenceResearch Group on Complex Collaboration, Faculty of Management, McGill University, 1001 Sherbrooke Street West, Montreal, QC H3A 1G5, Canada and Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, QC, Canada and Data-Enabled Life Sciences Alliance International (DELSA Global), Seattle, WA, USA. Published Online:7 May 2013https://doi.org/10.2217/pme.13.10AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail Keywords: genomics and developmentgenomics without bordersglobal governance of biotechnology innovation and uncertaintyLGBT communityLMICpublic health pharmacogenomicreflexive technology governanceresponsible innovationscience and technology studiestaxonomy of knowledge-based innovationTaking innovation from the clinic to the streetsThe now decade-old postgenomic era is marked with stories of triumph and tribulation, hope and hype, and gradual, sometimes serendipitous, innovations in personalized medicine [1]. While governments have prioritized research and development (R&D) and moving discoveries from laboratory to innovation [2], innovations (especially those in the biotechnology sector) have often underwhelmed governments, investors and the public in terms of utility [101]. The postgenomic era now includes direct-to-consumer genomics and is moving into its second decade [3]. We suggest that the personalized medicine innovation system is highly fluid and in flux as a result of fiscal restraint, and old ways of understanding innovations' nature and predictability are undergoing transformation. Much of the western world is now locked in a straightjacket of budgetary constriction; past calls for more R&D funding simply will not do as the fight for increasingly small resources intensifies and citizens resist the idea of greater taxation. New ways of conceptualizing innovation must take hold, embracing uncertain, contingent, discursive processes and questioning prior unchecked assumptions, values and constraints in the innovation system.We propose a new taxonomy for the 'public health pharmacogenomics' innovation ecosystem [4,5], labeled 'actors' and 'narrators', which takes innovation out of the laboratory and into the 'streets', and examines the embedded interests and unchecked power structures impacting knowledge coproduction among the innovation actors.Actors & narrators: a new taxonomy for innovation ecosystemsInnovations are now being understood, given their financial and societal significance, as engaged practices that move discursively in a knowledge ecosystem. While we certainly support the extant move toward 'opening up' the discussion on scientific design [6], there is a danger in succumbing to a false sense of assuredness that simply by bringing more people to the table, the innovation system will magically be more ethically just and socially robust. We cannot merely wish it so.To avoid falling into the trap of tokenism or unidirectional political legitimacy (i.e., more is always better), research funding agencies invested in pharmacogenomics and traditional innovation actors, such as academic scientists, industry and governments, must remain cognizant that aggregating publics and creating more time and space for dialogue do not necessarily lead to innovation or to better innovation that is sustainable [7]. Multitudes of voices and opinions, brought together without a sound social theory, can be cacophonous, counterproductive and at risk for tokenism [8].One of us (V Özdemir) has outlined a new taxonomy for understanding innovations and the attendant knowledge ecosystems as consisting of actors and narrators [9]. In this taxonomy, innovation actors – those who carry out core discovery and translational work, such as pharmacogenomic scientists – are situated at arm's length from first-order narrators, such as social scientists, lawyers, philosophers and bioethicists, who, armed with their own variable form of expertise, are acknowledged to play a critical role in exploring the ethical, legal and social implications of postgenomics research for individuals, families and communities. However, as with innovation actors, first-order narrators never come free of social interests or implications. In our proposed nested governance frame for knowledge-based innovations [9], first-order narrators are subject to engagement by experience-based second-order narrators, such as citizen scholars, knowledge endusers and traditionally marginalized groups, so as to prevent actors and first-order narrators from gaining excessive power that can be misused in the course of steering innovations. This dual ordering of narrators, as distinct from actors, is crucial for the additional reasons we explain below.Listening to the sound of silence: toward a sociology of bioethicsWe have long seen the emergence of different professionals, such as social scientists, bioethicists and philosophers, engaged in a narrator role in pharmacogenomics, but our taxonomy of knowledge coproduction noted above takes the actor–narrator dialectic to a greater level of accountability by underscoring that first-order narrators also have self-interests that ought to be made explicit for innovations to be transparent, sustainable and trustworthy to its constituents. For example, the well-known careerism that is endemic in academia, industry, governments and the 21st century workplace, or personal career interests of individuals, can taint the narrators' account of the innovation actors. Just as scientists are not immune to partisanship [10], innovation narrators are also rooted in the partisan fray, although latent it often may be. Yet narrators have so far not been subjected to this higher level of accountability, despite the trailblazing work of some 'bioethics observers' such as De Vries, Fox and Swazey, who have in essence advocated for an 'ethics of bioethics' or 'sociology of bioethics' so as to unpack and explicate these tensions embedded in an unchecked narrator role [11,12].We propose the concept of a second-order narrator precisely to address this accountability gap among the classic first-order narrators, while recognizing and endorsing their importance in the postgenomics innovation knowledge ecosystem. Moreover, we suggest that for innovations to be integrated 'sociotechnically' and embedded in societal values and, therefore, be robust, as advocated by leading genomics R&D funding agencies such as the Wellcome Trust, Genome Canada and the NIH, we need such nested and self-calibrating governance systems to respond to the uncertainties of biotechnology and postgenomic knowledge.The taxonomy of innovation as actors and nested narrator systems is also important for being truly inclusive in a manner informed by inherent power differences among the constituents of an innovation ecosystem. In effect, our proposed taxonomy guides decisions as to how we select different innovation actors in an engagement practice for innovations, and how we define inclusivity beyond the false face value of simply including some 'player' in a staging role. Much of the extant personalized medicine engagement exercises have been narrowly framed and do not include second-order narrators. In accordance with this, De Vries has aptly noted: "Sociology and bioethics have an uneasy relationship. Bioethicists find sociology helpful for describing and analyzing ethical issues, but they are less enthusiastic when bioethics becomes the subject of sociological scrutiny" [12].This observation also underscores that the role of a second-order innovation narrator is not a popularity contest, and is subject to professional marginalization, but it is essential for credibility and long-term sustainability of personalized medicine innovations and building a 21st century knowledge society.A taxonomy of actors and dual-order narrators takes the concept of innovation systems to a new level of stringency and standards. It is not a matter of simply thinking who is included or not, but instead thinking about the hitherto unchecked power systems and self-interests at play, and their consequential and collateral effects, on the postgenomics stage. These self-interests are neither necessarily malignant nor benevolent; interests and inescapable politics embedded in science and technology practice and, in due course, innovations, do exist [13]. Ultimately, the uptake of pharmacogenomics might be improved if both scientific and bioethics (and attendant social science, philosophy and law) institutions expressed an equivalent reflexive discourse; that is, being cognizant of how our own values and silent-value commitments impact the conclusions we reach (e.g., ethical/unethical technology, person and company).Taking innovations to the citizens of low- & middle-income countriesThis interconnectedness matters, for there is another neglected but important aspect to consider for both sets of the innovation constituents: actors and narrators not only have self-interests, but may be reluctant to come out and engage or participate in the innovation ecosystems because doing so may risk their wellbeing, safety or careers. Consider, for example, the case of hypersensitivity reaction to abacavir, a nucleoside reverse transcriptase inhibitor drug used in persons with HIV infection. This serious hypersensitivity, occurring in up to 9% of persons receiving abacavir, has a strong genetic component associated with the MHC allele, HLA-B*5701. The genetic testing for this variant is now recommended in clinical guidelines and is practiced in most western countries [14]. However, advocating for availability or distribution of, or seeking, HIV therapy in many low- and middle-income countries (LMICs), let alone abacavir genetic testing for its personalized use, may trigger severe, irreversible social consequences. At the extreme but not uncommon end, it can lead to the disclosure of the HIV status of an individual. Stigma, ostracization and discrimination can result, with assumptions that an advocate is wrongfully aligned with an infected person who allegedly has a 'sinful' lifestyle, be it as a drug user, sex worker or lesbian, gay, bisexual and transgendered (LGBT) person, not recognizing (at the very least) that HIV is an epidemic that affects all of society.Moreover, while citizens may turn to legal protection to combat these potentially negative reactions, there is a vast disconnect between 'the law on the streets' and 'the law in the books'; people who risk marginalization may find that turning to the law for support is limited or can even be futile in some LMICs [15]. Seen in this light, all the stage players cannot readily come together to build scientific knowledge. Narrators can serve the role of interactional expert advocates for marginalized innovation actors.Moving outside our pharmacogenomics echo chamber for sustainable innovationIn the envisioned postgenomic worlds, upon which a stage of narrators and actors perform innovative practices and deliver innovative technologies, we strongly advocate for the need to think outside our self- or socially assigned actor or narrator roles. Removing systemic obstacles to the health and wellbeing of all involves engagement in an innovation ecosystem that is truly inclusive both on paper and the streets, when technologies such as pharmacogenomics applications are being used for abacavir testing in LMIC for LGBTs and other marginalized groups.Sadly, we still live in a world riddled with racism, sexism, xenophobia, anti-Semitism, bullying and homophobia. Moreover, 'extreme neutrality', that is, conscious indifference stemming from a self-serving desire to remain popular with those in power, is another endemic ill in our global society, be it in LMICs or non-LMICs. We in the field of public policy, science and technology studies, law, pharmacogenomics, public health and personalized medicine can do our part, starting with including LMIC LGBT individuals as a legitimate part of the discourse in technologies that affect them, as well as other marginalized groups such as women in LMICs who may benefit from certain genetic tests for drug therapy.Engagement or advocacy on behalf of the disadvantaged groups is equally as important and should be carried out both by self-identifying members of these groups and also outsiders who believe in social justice as a principle [9,15,16].In the current era, when pharmacogenomics application are often advancing to public health practice and from developed countries to LMICs, it is noteworthy that truly groundbreaking work is more likely to appear from marginal, dissident or unexpected sources, rather than from the well-established and entrenched powerful mainstream. While this is well recognized within the arts community (consider, for example, the innovative graffiti art and the chalk figures drawn by Keith Haring on New York City subway posters in the 1980s outside the exclusivist gallery and museum system [17]), the emergence of new unprecedented forms of public health pharmacogenomic knowledge will demand a keen knowledge of both global and local knowledge [18]. Only through such a nuanced and integrated approach can a nested and freely engaged multilayer innovation ecosystem be designed and sustained, including in LMICs [9,19].In the face of the deep fault lines that fracture 21st century human civilization and communities, which stand on an increasingly unsustainable and precarious pedestal, understanding the nature of innovation actors and first- and second-order narrators will pave the way not only for pharmacogenomics action on the streets, but also an open society [102] where the public can assume the role of actors as citizen scientists, as well as narrators of the first and second kind. Such hybridity is to be cherished, for it is intrinsically good and a conditio sine qua non for socially robust and sustainable postgenomic personalized medicine.Authors' contributionThe idea of actors and dual-order narrators was proposed by V Özdemir in a former paper, wherein the concept of wiki-governance was proposed by ES Dove to operate such nested innovation knowledge ecosystems.DisclaimerThe views and analysis reported herein are entirely the authors' personal opinions and do not represent the views of the affiliated institutions nor the funding agencies. Both ES Dove and V Özdemir are second-order narrators of postgenomics biotechnology and knowledge-based innovation. ES Dove is a sociolegal scholar and V Özdemir is a pharmacogenomics scientist and medical doctor by training.Financial & competing interests disclosureThe analysis, concepts and work reported herein were informed and supported by the following research grants to V Özdemir: Canadian Institutes of Health Research operating research grant, number 84620, on pharmacogenomics policy, and a research grant from the Social Sciences and Humanities Research Council, 231644, on emerging biotechnology foresight research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.References1 Tutton R. Personalizing medicine: futures present and past. Soc. Sci. Med.75(10),1721–1728 (2012).Crossref, Medline, Google Scholar2 Özdemir V, Muljono DH, Pang T et al. Asia–Pacific Health 2020 and Genomics without Borders: co-production of knowledge by science and society partnership for global personalized medicine. Curr. Pharmacogenomics Person. Med.9(1),1–5 (2011).Crossref, Medline, CAS, Google Scholar3 Vayena E, Gourna E, Streuli J, Hafen E, Prainsack B. Experiences of early users of direct-to-consumer genomics in Switzerland: an exploratory study. Public Health Genomics15(6),352–362 (2012).Crossref, Medline, CAS, Google Scholar4 Özdemir V, Fisher E, Dove ES et al. End of the beginning and public health pharmacogenomics: knowledge in 'mode 2' and P5 medicine. Curr. Pharmacogenomics Person. Med.10(1),1–6 (2012).Crossref, Medline, CAS, Google Scholar5 Özdemir V, Borda-Rodriguez A, Dove ES et al. Public health pharmacogenomics and the design principles for global public goods – moving genomics to responsible innovation. Curr. Pharmacogenomics Person. Med.11(1),1–4 (2013).Crossref, Medline, CAS, Google Scholar6 Stirling A. 'Opening up' and 'closing down': power, participation, and pluralism in the social appraisal of technology. Sci. Technol. Human Values33(2),262–294 (2008).Crossref, Google Scholar7 Wynne B. Misunderstood misunderstanding: social identities and public uptake of science. Public Underst. Sci.1(3),281–304 (1992).Crossref, Google Scholar8 Wynne B. Public engagement as a means of restoring public trust in science – hitting the notes, but missing the music? Community Genet.9(3),211–220 (2006).Crossref, Medline, Google Scholar9 Dove ES, Faraj SA, Kolker E, Ozdemir V. Designing a post-genomics knowledge ecosystem to translate pharmacogenomics into public health action. Genome Med.4(11),91 (2012).Crossref, Medline, Google Scholar10 Guston DH, Sarewitz D, Miller C. Scientists not immune to partisanship. Science323(5914),582 (2009).Crossref, Medline, CAS, Google Scholar11 Fox RC, Swazey JP. Observing Bioethics. Oxford University Press, Oxford, UK (2008).Google Scholar12 De Vries R. How can we help? From 'sociology in' to 'sociology of' bioethics. J. Law Med. Ethics32(2),279–292 (2003).Crossref, Google Scholar13 Dove ES, Özdemir V. 'Regular science' is inherently political. EMBO Rep.14(2),113 (2013).Crossref, Medline, CAS, Google Scholar14 Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br. J. Clin. Pharmacol.71(5),659–671 (2011).Crossref, Medline, CAS, Google Scholar15 Özdemir V. What to do when the risk environment is rapidly shifting and heterogeneous? Anticipatory governance and real-time assessment of social risks in multiply marginalized populations can prevent IRB mission creep, ethical inflation or underestimation of risks. Am. J. Bioeth.9(11),65–68 (2009).Crossref, Medline, Google Scholar16 Epstein S. Impure Science: AIDS, Activism, and the Politics of Knowledge. University of California Press, CA, USA (1996).Google Scholar17 Aubert E, Haring K, Hopper D et al.Drawing The Line: A Portrait of Keith Haring. Cohn A, Wolff JS (Eds.). Biografilm Associates, NJ, USA (1989).Google Scholar18 Özdemir V. OMICS 2.0: a practice turn for 21(st) century science and society. OMICS17(1),1–4 (2013).Crossref, Medline, Google Scholar19 Dove ES, Joly Y, Knoppers BM. Power to the people: a wiki-governance model for biobanks. Genome Biol.13,158 (2012).Crossref, Medline, Google Scholar101 Nuffield Council on Bioethics. Emerging Biotechnologies: Technology, Choice and the Public Good. Nuffield Council on Bioethics, London, UK (2012).. www.nuffieldbioethics.org/sites/default/files/Emerging_biotechnologies_full_report_web_0.pdfGoogle Scholar102 Vaclav Havel. Address by Czech Republic President Vaclav Havel in acceptance of 'Open Society' Prize by the Central European University, Budapest, Hungary, 24 June 1999. http://old.hrad.cz/president/Havel/speeches/1999/2406_uk.htmlGoogle ScholarFiguresReferencesRelatedDetailsCited ByRegulatory sciences and translational pharmacogenetics: amitriptyline as a case in pointDrug Metabolism and Personalized Therapy, Vol. 34, No. 2A Mobilising Concept? Unpacking Academic Representations of Responsible Research and Innovation8 March 2016 | Science and Engineering Ethics, Vol. 23, No. 1IntroductionPersonalized MedicineWithin and beyond the communal turn to informed consent in industry-sponsored pharmacogenetics research: merits and challenges of community advisory boards5 August 2016 | Journal of Community Genetics, Vol. 7, No. 4From big data analysis to personalized medicine for all: challenges and opportunities27 June 2015 | BMC Medical Genomics, Vol. 8, No. 1Pharmacogenetics through a public health lensPharmacogenetics and Genomics, Vol. 25, No. 10A Delphi Technology Foresight Study: Mapping Social Construction of Scientific Evidence on Metagenomics Tests for Water Safety11 June 2015 | PLOS ONE, Vol. 10, No. 6A Code of Ethics for Ethicists: What Would Pierre Bourdieu Say? "Do Not Misuse Social Capital in the Age of Consortia Ethics"13 May 2015 | The American Journal of Bioethics, Vol. 15, No. 5Translating Biotechnology to Knowledge-Based Innovation, Peace, and Development? Deploy a Science Peace Corps—An Open Letter to World LeadersOMICS: A Journal of Integrative Biology, Vol. 18, No. 7Special Issue "OMICS IN AFRICA": Power to the People—Moving 21st Century Integrative Biology from Lab to Village to Innovation EcosystemsOMICS: A Journal of Integrative Biology, Vol. 18, No. 7Glocal Bioethics: When International IRB Collaboration Confronts Local Politics25 April 2014 | The American Journal of Bioethics, Vol. 14, No. 5Ready to Put Metadata on the Post-2015 Development Agenda? Linking Data Publications to Responsible Innovation and Science DiplomacyOMICS: A Journal of Integrative Biology, Vol. 18, No. 1Crowd-Funded Micro-Grants for Genomics and "Big Data": An Actionable Idea Connecting Small (Artisan) Science, Infrastructure Science, and Citizen PhilanthropyOMICS: A Journal of Integrative Biology, Vol. 17, No. 4 Vol. 10, No. 3 Follow us on social media for the latest updates Metrics History Published online 7 May 2013 Published in print May 2013 Information© Future Medicine LtdKeywordsgenomics and developmentgenomics without bordersglobal governance of biotechnology innovation and uncertaintyLGBT communityLMICpublic health pharmacogenomicreflexive technology governanceresponsible innovationscience and technology studiestaxonomy of knowledge-based innovationAuthors' contributionThe idea of actors and dual-order narrators was proposed by V Özdemir in a former paper, wherein the concept of wiki-governance was proposed by ES Dove to operate such nested innovation knowledge ecosystems.DisclaimerThe views and analysis reported herein are entirely the authors' personal opinions and do not represent the views of the affiliated institutions nor the funding agencies. Both ES Dove and V Özdemir are second-order narrators of postgenomics biotechnology and knowledge-based innovation. ES Dove is a sociolegal scholar and V Özdemir is a pharmacogenomics scientist and medical doctor by training.Financial & competing interests disclosureThe analysis, concepts and work reported herein were informed and supported by the following research grants to V Özdemir: Canadian Institutes of Health Research operating research grant, number 84620, on pharmacogenomics policy, and a research grant from the Social Sciences and Humanities Research Council, 231644, on emerging biotechnology foresight research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download